Palatin Files $100M Shelf Registration While Carrying a Going-Concern Warning
PTN is trading near its 52-week low of $4.51 (1.6% above the low) on light trading volume (0.3× avg).
Summary
Palatin filed a $100 million shelf registration, giving it the ability to sell securities over time — though its roughly $17.4 million public float caps actual primary sales at about one-third of that per year. No shares have been sold yet.
Key Events · Financing and Capital Events · PTN
-
New $100M Shelf Registered
The Form S-3 covers up to $100,000,000 of common stock, preferred stock, debt securities, warrants, purchase contracts and units, to be sold from time to time. No securities have been sold under it.
-
Float Cap Limits Real Proceeds
Public float is approximately $17,391,392, so General Instruction I.B.6 limits primary sales to one-third of float — roughly $5.8 million — in any 12-month period while float stays below $75 million.
-
Cash Position Makes Raise Likely
The company had $3.74 million on hand after burning $3.74 million in the September quarter and has repeated its going-concern warning, so the shelf is the vehicle for the next capital raise.
-
Proceeds Earmarked for R&D
Net proceeds are designated for general corporate purposes, including preclinical and clinical development of the MC4R obesity agonist programs, plus working capital and capital expenditures.
Analysis · PTN · Life Sciences
Palatin has registered the right to sell up to $100 million of stock, preferred, debt, warrants, purchase contracts and units from time to time — no shares have been sold, and each actual sale requires its own prospectus supplement. The practical constraint is far smaller than the headline: with public float of about $17.4 million, General Instruction I.B.6 caps primary sales at roughly one-third of float, about $5.8 million, in any 12-month window. Against $3.74 million of cash at September 30 and a repeated going-concern warning, this is the company setting up the mechanism to keep funding its MC4R obesity programs — and it puts a dilution overhang on a stock already trading near its 52-week low.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PTN was trading at $4.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $4.51 to $31.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.